EMA: New Q&A on Supply Chain Traceability
The EMA has revised the Q&As on good manufacturing and distribution practices (GMPs/GDPs). A new question and answer on the documentation of supply chain traceability has been added to the section about EU GMP Guide Annex 16 certification by a qualified person and batch release.
The question:
How should the traceability of the supply chain of the active substance and medicinal product be documented to support the Qualified Person batch certification and release.
EMA’s response:
- To meet the certification requirements in Section 1 of EU GMP Guide Annex 16, the entire manufacturing and distribution supply chain of the medicinal product and its active substance must be documented and available to the Qualified Person.
- Supply chain records should ensure traceability, be available promptly, and support activities like quality defect investigations, product recalls, or requests from authorities.
- These records should identify all entities, including suppliers and outsourced services, involved in manufacturing each batch, as per the registered supply chain.
- Additionally, in line with Chapters 1 and 5 of EU GMP Guide Part I, supply chain traceability risks should be formally assessed, periodically reviewed, and mitigated with appropriate measures.
Source:
EMA: Guidance on good manufacturing practice and good distribution practice: Questions and answers
Meet the GMP Compliance Adviser
The GMP Compliance Adviser is the world's largest knowledge portal for quality management in the pharma business.
The demo access is non-binding and ends automatically.
You may also be interested in the following articles:
